These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

677 related articles for article (PubMed ID: 33664747)

  • 1. PDIA5 is Correlated With Immune Infiltration and Predicts Poor Prognosis in Gliomas.
    Zhang H; He J; Dai Z; Wang Z; Liang X; He F; Xia Z; Feng S; Cao H; Zhang L; Cheng Q
    Front Immunol; 2021; 12():628966. PubMed ID: 33664747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protein disulfide isomerases are promising targets for predicting the survival and tumor progression in glioma patients.
    Peng Z; Chen Y; Cao H; Zou H; Wan X; Zeng W; Liu Y; Hu J; Zhang N; Xia Z; Liu Z; Cheng Q
    Aging (Albany NY); 2020 Feb; 12(3):2347-2372. PubMed ID: 32023222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TNFSF13 Is a Novel Onco-Inflammatory Marker and Correlates With Immune Infiltration in Gliomas.
    Chen R; Wang X; Dai Z; Wang Z; Wu W; Hu Z; Zhang X; Liu Z; Zhang H; Cheng Q
    Front Immunol; 2021; 12():713757. PubMed ID: 34712225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Orphan nuclear receptor TLX promotes immunosuppression via its transcriptional activation of PD-L1 in glioma.
    Zhou J; Pei X; Yang Y; Wang Z; Gao W; Ye R; Zhang X; Liu J; Liu Z; Yang X; Tao J; Gu C; Hu W; Chan FL; Li X; Mao J; Wu D
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33858847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FAM109B plays a tumorigenic role in low-grade gliomas and is associated with tumor-associated macrophages (TAMs).
    Zhang Z; Xiao Y; Zhao S; Liu J; Zeng J; Xiao F; Liao B; Shan X; Zhu H; Guo H
    J Transl Med; 2024 Sep; 22(1):833. PubMed ID: 39256832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Four-Gene Panel for the Prediction of Prognosis and Immune Cell Enrichment in Gliomas.
    Li Z; Jin Y; Zhang P; Zhang XA; Yi G; Zheng H; Yuan X; Wang X; Xu H; Qiu X; Chen C; Que T; Huang G
    Mol Biotechnol; 2024 Sep; 66(9):2308-2321. PubMed ID: 37644261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CLEC7A regulates M2 macrophages to suppress the immune microenvironment and implies poorer prognosis of glioma.
    Wang J; Li X; Wang K; Li K; Gao Y; Xu J; Peng R; Zhang X; Zhang S; Zhou Y; Xu S; Zhang J
    Front Immunol; 2024; 15():1361351. PubMed ID: 38846954
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Hu Z; Qu S
    Front Immunol; 2021; 12():683572. PubMed ID: 34267752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PDIA3 correlates with clinical malignant features and immune signature in human gliomas.
    Zhang H; Zhou Y; Cheng Q; Dai Z; Wang Z; Liu F; Fan F; Cui B; Cao H
    Aging (Albany NY); 2020 Aug; 12(15):15392-15413. PubMed ID: 32687065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protein disulphide isomerase can predict the clinical prognostic value and contribute to malignant progression in gliomas.
    Hu Q; Huang K; Tao C; Zhu X
    J Cell Mol Med; 2020 May; 24(10):5888-5900. PubMed ID: 32301283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pan-Cancer Analysis of the Immunological Role of PDIA5: A Potential Target for Immunotherapy.
    Chen Y; He J; Chen R; Wang Z; Dai Z; Liang X; Wu W; Luo P; Zhang J; Peng Y; Zhang N; Liu Z; Zhang L; Zhang H; Cheng Q
    Front Immunol; 2022; 13():881722. PubMed ID: 36003400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrated bioinformatics analysis and experimental validation reveal the relationship between ALOX5AP and the prognosis and immune microenvironment in glioma.
    Song P; Deng H; Liu Y; Zhang M
    BMC Med Genomics; 2024 Aug; 17(1):218. PubMed ID: 39169376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ITGB2 as a prognostic indicator and a predictive marker for immunotherapy in gliomas.
    Xu H; Zhang A; Han X; Li Y; Zhang Z; Song L; Wang W; Lou M
    Cancer Immunol Immunother; 2022 Mar; 71(3):645-660. PubMed ID: 34313821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrated bioinformatics analysis and experimental validation on malignant progression and immune cell infiltration of LTBP2 in gliomas.
    Gao L; Zhang R; Zhang W; Lan Y; Li X; Cai Q; Liu J
    BMC Cancer; 2024 Oct; 24(1):1252. PubMed ID: 39390437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon regulatory factor transcript levels correlate with clinical outcomes in human glioma.
    Lei J; Zhou MH; Zhang FC; Wu K; Liu SW; Niu HQ
    Aging (Albany NY); 2021 Apr; 13(8):12086-12098. PubMed ID: 33902005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glioma hexokinase 3 positively correlates with malignancy and macrophage infiltration.
    Liang T; Zhou X; Wang Y; Ma W
    Metab Brain Dis; 2024 Jun; 39(5):719-729. PubMed ID: 38687460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MXRA5 Is a Novel Immune-Related Biomarker That Predicts Poor Prognosis in Glioma.
    Sun JZ; Zhang JH; Li JB; Yuan F; Tong LQ; Wang XY; Chen LL; Fan XG; Zhang YM; Ren X; Zhang C; Yu SP; Yang XJ
    Dis Markers; 2021; 2021():6680883. PubMed ID: 34211612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic prediction and immune checkpoint profiling in glioma patients through neddylation-associated features.
    Qi J; Li L; Gao B; Dai K; Shen K; Wu X; Li H; Yu Z; Wang Z; Wang Z
    Gene; 2024 Dec; 930():148835. PubMed ID: 39127414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated expression of DOK3 indicates high suppressive immune cell infiltration and unfavorable prognosis of gliomas.
    Liu X; Chen F; Li W
    Int Immunopharmacol; 2020 Jun; 83():106400. PubMed ID: 32193105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High expression of SIGLEC7 may promote M2-type macrophage polarization leading to adverse prognosis in glioma patients.
    An W; Ren C; Yuan L; Qiu Z; Wang P; Cheng Y; He Z; Han X; Li S; An Y
    Front Immunol; 2024; 15():1411072. PubMed ID: 39211050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.